Granules India Ltd receives approval from the Health Canada for Acetaminophen Extended-Release Tablets

Granules India Limited announced receiving marketing approval from Health Canada for Acetaminophen Extended-Release Tablets OTC, 650mg for the treatment of Arthritis Pain. The product manufactured by Granules is a bioequivalent to the reference listed drug, Tylenol® Extended Release 650 Tablets.

Priyanka Chigurupati, Executive Director of Granules USA, Inc. & Granules Pharmaceuticals, Inc. said, "We received the approval within eight months of filing. This is a step towards global expansion of our core molecules. The approval of Acetaminophen Extended-Release Tablets OTC, 650mg, a complex Bi-layer Extended Released based formulations, is a good addition to our portfolio. We will be launching the product in the Canada market soon."

The drug will be manufactured at the Granules manufacturing facility located in Gagillapur, Hyderabad. Granules now have a total of 2 ANDS approvals from Health Canada.

Shares of Granules India Ltd. was last trading in BSE at Rs. 330.85 as compared to the previous close of Rs. 326.25. The total number of shares traded during the day was 101633 in over 1878 trades.

The stock hit an intraday high of Rs. 333.6 and intraday low of 323.5. The net turnover during the day was Rs. 33497114.

Source : Equity Bulls

Keywords